Spots Global Cancer Trial Database for Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test

Official Title: Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test

Study ID: NCT05176145

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

VisioCyt®

Study Description

Brief Summary: European, multicenter clinical trial with VisioCyt®, an in vitro diagnostic medical device. VisioCyt® is an innovative solution for the early diagnosis of bladder cancer.

Detailed Description: VisioCyt® is based on a patented technology, combining bright-field imaging and artificial intelligence, from a simple urine sample from which the cells are extracted . The main objective of the study is to demonstrate the medical superiority of the VisioCyt® test versus conventional cytology for detecting recurrence of bladder tumors, in patients monitoring non-muscle infiltrating bladder tumors at high and very high risk of progression